Genetic prognostic and predictive markers in colorectal cancer

Axel Walther ¹, Elaine Johnstone , Charles Swanton

⁰Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK.

Nature Reviews. Cancer +

|

June 19, 2009

View abstract on PubMed

Summary

Understanding colorectal cancer prognosis is improving with new molecular markers. The KRAS mutation guides epidermal growth factor receptor (EGFR) therapy, personalizing treatment for better patient outcomes.

Area Of Science

Oncology
Molecular Biology
Genetics

Background

Colorectal cancer patient survival outcomes are poorly understood.
Individual patient responses to therapy remain largely unknown.
Recent discoveries are beginning to enable personalized cancer treatment.

Purpose Of The Study

To review and critically assess prognostic and treatment outcome markers for colorectal cancer.
To clarify the evolving landscape of molecular markers in colorectal cancer.
To provide an overview of current knowledge on colorectal cancer patient stratification.

Main Methods

Review of existing literature on colorectal cancer prognostic markers.
Analysis of molecular markers, including KRAS mutations.
Assessment of high-throughput screening data and public domain markers.

Main Results

The KRAS mutation is a key marker for predicting epidermal growth factor receptor (EGFR)-targeted therapy failure.
Numerous molecular markers are emerging for prognosis and treatment outcome prediction.
Significant advancements in molecular analyses are enhancing understanding of colorectal cancer.

Conclusions

Personalized medicine in colorectal cancer is advancing, driven by molecular markers.
The KRAS mutation represents a significant step towards tailored colorectal cancer therapy.
Continued research into molecular markers is crucial for improving patient survival and treatment efficacy.

Related Concept Videos